Transcode Therapeutics Inc
General ticker "RNAZ" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $80.3M
Transcode Therapeutics Inc does not follow the US Stock Market performance with the rate: -22.9%.
Estimated limits based on current volatility of 15.0%: low 3.24$, high 4.38$
Factors to consider:
- Current price 96.7% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [107.59$, 722.05$]
- 2024-12-30 to 2025-12-30 estimated range: [30.08$, 175.55$]
Financial Metrics affecting the RNAZ estimates:
- Negative: Non-GAAP EPS, $ of -562.79 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -92.72 <= 2.35
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
Short-term RNAZ quotes
Long-term RNAZ plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $6.15MM | $18.67MM | $19.42MM |
| Operating Income | $-6.15MM | $-18.67MM | $-19.42MM |
| Non-Operating Income | $-0.69MM | $1.10MM | $0.87MM |
| Interest Expense | $0.10MM | $17.56MM | $0.05MM |
| R&D Expense | $2.75MM | $10.23MM | $12.26MM |
| Income(Loss) | $-6.84MM | $-17.56MM | $-18.55MM |
| Profit(Loss) | $-6.84MM | $-17.56MM | $-18.55MM |
| Stockholders Equity | $20.40MM | $3.24MM | $1.64MM |
| Inventory | $0.00MM | $0.55MM | $0.00MM |
| Assets | $22.94MM | $7.59MM | $5.17MM |
| Operating Cash Flow | $-5.27MM | $-15.76MM | $-18.07MM |
| Capital expenditure | $0.25MM | $0.10MM | $0.04MM |
| Investing Cash Flow | $-0.25MM | $-0.10MM | $-0.04MM |
| Financing Cash Flow | $25.52MM | $0.01MM | $15.91MM |
| Earnings Per Share* | $-658.80 | $-2,195.62 | $-103.61 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.